Top of page

OxPLoreD: a study to find out more about pre-cancerous blood conditions

This study does not involve any treatment. The researchers will ask participants with some early-stage pre-cancerous blood conditions to donate blood samples and to fill out questionnaires. Some participants will also be asked for a liquid bone marrow sample.


Trial aim and background

Only 1 in 20 people with pre-cancerous blood conditions are likely to go on to develop blood or bone marrow cancer. The aim of this study is to find a more precise way to predict which people are likely to be affected by blood or bone marrow cancer. 

The study will monitor people with early-stage pre-cancerous blood conditions that do not currently need treatment. This will include people with early-stage chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), monoclonal B-cell lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS), early stage myeloma and Waldenström’s macroglobulinaemia (WM) that is not causing any symptoms.

Participants will be studied for up to 5 years with study visits at the beginning, after 2 years and at disease progression. They will be asked about what it is like to have an early-stage pre-cancerous blood condition. The researchers will also collect information about any other health problems participants have.


Who can enter

People over 16  who have been diagnosed with stage 1 or 2 CLL/SLL no requiring treatment and Waldenström’s macroglobulinaemia that is not causing any symptoms and does not need treatment may be eligible for this trial.

Around 1,650 people are needed for this trial.


Locations

Recruitment is taking place in the following UK locations:

  • The Christie NHS Foundation Trust, Manchester
  • Norfolk and Norwich University Hospitals NHS Trust, Norwich
  • Oxford University Hospitals NHS Foundation Trust, Oxford
  • University Hospitals Plymouth NHS Trust, Plymouth
  • Royal Cornwall Hospital Trust, Truro

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: clinicaltrials.gov/ct2/show/NCT04023747.

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.